

November 27, 2021

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Clearance of Second Phase of Clinical Trial Study of "COROVYL" Ayurvedic tablet to be used in the management of Corona virus disease**

**Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject we, Zota Health Care Limited (the "Company") are delighted to inform you that our Ayurvedic tablet "**COROVYL**" has successfully cleared the second phase of clinical trial study. "**COROVYL**" Ayurvedic tablet to be used as Immune booster, Anti cold, Anti Inflammatory, Broncho Protective in the management of Corona virus disease.

The Clinical Trial Study has been conducted at Government Medical College and Government Medical Hospital Srikakulam. The study has been conducted under the supervision of Principal Investigator Dr. Sunil Naik. The Study has been conducted on both male and female subjects having age between 18 to 60 years and having positive or pharyngeal/ nasal swab RT-PCR for Sars- Co- V2. diagnosed not more than 2 days ago and either asymptomatic or have mild to moderate symptoms.

The above Study has been registered with Clinical Trail Registry of India headed by ICMR - National Institute of Medical Statistic and they have insured the study.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat



**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj) India  
Ph: +91 261 2397122